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Abstract
Background: Dual-specificity phosphatase-5 (DUSP5) plays a central role in vascular development and disease. We
present a p-nitrophenol phosphate (pNPP) based enzymatic assay to screen for inhibitors of the phosphatase
domain of DUSP5.
Methods: pNPP is a mimic of the phosphorylated tyrosine on the ERK2 substrate (pERK2) and binds the DUSP5
phosphatase domain with a Km of 7.6 ± 0.4 mM. Docking followed by inhibitor verification using the pNPP assay
identified a series of polysulfonated aromatic inhibitors that occupy the DUSP5 active site in the region that is likely
occupied by the dual-phosphorylated ERK2 substrate tripeptide (pThr-Glu-pTyr). Secondary assays were performed
with full length DUSP5 with ERK2 as substrate.
Results: The most potent inhibitor has a naphthalene trisulfonate (NTS) core. A search for similar compounds in a
drug database identified suramin, a dimerized form of NTS. While suramin appears to be a potent and competitive
inhibitor (25 ± 5 μM), binding to the DUSP5 phosphatase domain more tightly than the monomeric ligands of
which it is comprised, it also aggregates. Further ligand-based screening, based on a pharmacophore derived from
the 7 Å separation of sulfonates on inhibitors and on sulfates present in the DUSP5 crystal structure, identified a
disulfonated and phenolic naphthalene inhibitor (CSD3_2320) with IC50 of 33 μM that is similar to NTS and does
not aggregate.
Conclusions: The new DUSP5 inhibitors we identify in this study typically have sulfonates 7 Å apart, likely
positioning them where the two phosphates of the substrate peptide (pThr-Glu-pTyr) bind, with one inhibitor also
positioning a phenolic hydroxyl where the water nucleophile may reside. Polysulfonated aromatic compounds do
not commonly appear in drugs and have a tendency to aggregate. One FDA-approved polysulfonated drug,
suramin, inhibits DUSP5 and also aggregates. Docking and modeling studies presented herein identify
polysulfonated aromatic inhibitors that do not aggregate, and provide insights to guide future design of mimics of
the dual-phosphate loops of the ERK substrates for DUSPs.
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Background
Mitogen-activated protein kinases (MAPKs), such as
extracellular regulated kinase (ERK) [1], are activated by
phosphorylation of tyrosine and serine/threonine resi-
dues in their activation loops. MAPKs can then be deac-
tivated by phosphatases that remove these phosphate
groups from their activation loop. One such class of
phosphatases, dual-specificity phosphatases (DUSPs), is
unique in that it can dephosphorylate both serine/threo-
nine and tyrosine residues. The Ramchandran lab has
shown that DUSP5 is necessary for early vascular pat-
terning in vertebrates, and is mutated in patients with
vascular anomalies [2]. DUSP5 plays a regulatory role in
vascular development based on its ability to specifically
interact with and dephosphorylate phosphorylated ERK
(pERK) [3–7]. Indeed, we identified a clinically relevant
serine to proline mutation (S147P) that is associated
with vascular defects [2]. This mutation has been shown
previously by our group to interfere with the dephos-
phorylating activity of DUSP5 protein [8], and makes the
protein hypoactive. However, the direct causal role of
S147P in vascular anomaly progression is yet to be
established. Nevertheless, DUSP5 is a critical drug target
for vascular-related diseases, and more broadly, MAPKs
and their DUSP partners are involved in cell signaling
that is directly involved in a wide range of diseases, includ-
ing cancer, diabetes, and autoimmune disorders [6, 9–11].
Recently, DUSP5 has gained increased attention in the sci-
entific literature [12–14] especially as it relates to loss or
gain of expression of DUSP5 in murine models, and its as-
sociated phenotypic changes in both the immune and can-
cer biology systems. DUSP5 knockout (KO) mice are alive,
and display no overt phenotype, indicating that it is dis-
pensable for embryonic development. However, Holmes et
al did report that these mice showed increased function
and survival of eosinophils, a key player in the immune
system’s ability to clear parasitic infections [12]. Further,
Rushworth et al reported increased sensitivity to a skin
cancer model in their murine model [14]. In terms of the
vasculature, the DUSP5 KO rat displays enhanced myo-
genic response and autoregulation of cerebral blood flow
[15]. Taken together, these studies demonstrate that inhib-
ition of DUSP5 will result in biologically relevant changes
in vivo.
From a conformation perspective, DUSP5 is comprised
of two domains, an N-terminal ERK binding domain
(EBD) and a C-terminal phosphatase domain (PD) [5, 16].
While there is no structure available for intact DUSP5,
there is a crystal structure of the PD [162]. The DUSP5
PD structure has two anionic sulfate groups bound in
the active site near the catalytic Cys263 (mutated to
serine in the structure), and separated by 7.2 Å.
These sulfates had been proposed to occupy the same
binding pockets that are occupied by the phosphate
groups on the substrate [16]. For the ERK2 substrate,
the pThr-Glu-pTyr tripeptide region of the ERK2 acti-
vation loop presumably occupies this region in the
DUSP5 PD [17, 18].
A molecular model based on the crystal structures of
the human DUSP5 PD and ERK2, and a homology
model of the DUSP5 EBD, illustrates the bivalent nature
of the interaction between the two domains of DUSP5
and the ERK2 substrate (Fig. 1) [8]. The current study
has identified small molecule inhibitors that occupy the
active site pocket on the DUSP5 PD, and act as inhibi-
tors of the phosphatase enzymatic activity. We further
tested some of these compounds as inhibitors of full-
length DUSP5 and in in vitro assays, to relate inhibition
results and conclusions to more biologically and clinic-
ally relevant situations.
Methods
Molecular docking
The Center for Structure-based Drug Design and Devel-
opment (CSD3) chemical library, consisting of 11,500
drug-like chemicals, was prepared in electronic format
as two-dimensional (2D) SDF files. Using Pipeline Pilot
[19], the protonation state of all compounds was ad-
justed to reflect the most prevalent form at a pH of 7.4.
CORINA [20] was used to convert these files to three-
dimensional (3D) PDB coordinate files, which resulted
in energy-minimized 3D structures. The files were then
processed with the python script prepare_ligand4.py,
which comes with the Autodock Tools Suite [21]. This
script generates a pdbqt file and adds partial charges to
the ligand, sets all torsions in the ligand to active (to
permit rotation), and merges all non-polar hydrogen
atoms.
The DUSP5 PD structure (PDB:2G6Z) [16] was pre-
pared for docking using the Autodock Tools Suite [21].
Grid maps were used in the energy calculations per-
formed by Autodock. Partial charges were added and
all non-polar hydrogen atoms were merged, resulting
in a pdbqt file. The 13 different grid maps, one for
each of the different atoms present in the chemical
library of compounds (ex. C, H, F, Cl, etc.), were
generated using Autogrid4 [21]. A grid box, the site
used to dock the ligands, was positioned to cover the
entire protein in a blind docking experiment to en-
sure unbiased identification of binding location and
orientation.
The docking parameter file (dpf ), which contains the
parameters that Autodock4 uses to dock ligands into the
protein, was prepared using the python script prepar-
e_dpf4.py, and default docking parameters were used,
except that 50 separate docking calculations were per-
formed with each calculation consisting of 1,750,000 en-
ergy evaluations, and a root mean square deviation (rmsd)
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tolerance set to 2.0 angstroms (to define entry of structure
into a given cluster). The dpf files were then automatically
docked using the MUGrid Cluster (Marquette University)
with HTCondor [22, 23] and AutoDock4 [21, 24] using
the Lamarckian genetic algorithm local search method to
perform the optimization of docking poses. The docking
poses were then clustered on the basis of the rmsd be-
tween the coordinates of the atoms in a given ligand, and
were ranked on the basis of calculated free energy of
binding. The docking log files were then analyzed using
the python script summarize_results4.py contained in the
shell script sumresults_4.py [21], which rank orders all the
dockings by binding energy. The results were then ana-
lyzed to find the best-clustered compounds with lowest
free energy of binding as determined by Autodock4.2.
Additional docking of all experimentally tested chemicals
was performed as described above, but with 100 dockings
trials.
Fig. 1 DUSP5 and ERK2 Models. a Model depicting the two domains of DUSP5. This model is comprised of two domains, the ERK binding domain
(EBD) and phosphatase domain (PD), and illustrates the relative location of the domains and their connection via a 30 amino acid linker of unknown
structure. The homology model of EBD was constructed using the solution structure (21 % identity and 35 % homology) of human MKP-3 protein
(PDB:1HZM) as a template [35]. The phosphatase domain is the previously reported crystal structure (PDB:2G6Z) [16]. The 30 amino acid linker region
connecting the two domains was prepared manually, and is of unknown structure. The S147P mutation present in patients with vascular anomalies is
shown in green, and arginine-rich basic regions have been identified. b DUSP5 and ERK2 binding model. DUSP5 (blue) is positioned similarly in respects
to panel a with the EBD to the left and PD to the right, wrapping around human ERK2 in yellow. Model was prepared as described in our previous
paper [8]. The linker region may have the first 11 amino acids as helical based secondary structure predictions [46–48], although this was only found to
be loosely helical after molecular dynamics simulations. The ERK2 (yellow) structure (PDB:3I60) [18] is shown between the DUSP5 domains to illustrate
relative shape and size complementarity; and, relative orientation of ERK2 and DUSP5 is based on the molecular dynamics simulation and associated
analysis presented in our previous paper [8]
Neumann et al. BMC Biochemistry  (2015) 16:19 Page 3 of 16
Ligand-based searching
As previously described, the CSD3 chemical library was
electronically prepared and protonation state adjusted
using Pipeline Pilot [19]. Using OpenEye Scientific Soft-
ware’s Omega2 [25, 26], three dimensional coordinates
were calculated and stored in OpenEye Scientific Soft-
ware’s preferred file format, .oeb.gz, for subsequent mo-
lecular overlay evaluation. OpenEye Scientific Software’s
Rapid Overlay of Chemical Structures (ROCS) [25] soft-
ware was used to search for molecules with similar
shape and electronic properties to a lead molecule. Lead
molecules identified from DUSP5 docking and inhibition
studies were used as chemical queries to search a data-
base of Food and Drug Administration (FDA) approved
drugs, to identify FDA approved drugs that might also
be DUSP5 inhibitors.
The ZINC library [27] of 13 million commercially
available chemicals was obtained as 2D SDF files and
prepared similarly to the CSD3 chemical library for use
with OpenEye Scientific Software’s ROCS. This further
expanded the availability of chemical analogs available
for experimental screening. ROCS calculations were also
performed against the DrugBank [28, 29] database of
FDA approved drugs.
Synthesis of RR505 and RR506. Synthesis of
Carbazole-1,3,6-trisulfonic acid, trisodium salt (RR505)
Solid carbazole (3.0 g, 17.9 mmol) was placed in a 50-mL
round-bottom flask and 67 % H2SO4 (12 mL) was added
drop-wise at 22 °C and a slurry thus obtained was stirred
and heated at 115 ± 5 °C for 6 h. The resulting dark solu-
tion was cooled to room temperature and poured into a
saturated NaCl solution (100 mL) containing NaOH
(2.4 g, 60 mmol) to afford an ash-colored precipitate,
which was filtered, washed with saturated NaCl solution
(50 mL) and dried at 90 °C for 10 h to get 7.5 g of the
crude product.
The crude solid was dissolved in distilled/deionized
water (150 mL), treated with activated charcoal Norit
(1.1 g) and the resulting mixture was refluxed for
15 min. The solution was filtered hot through a pad of
Celite®, and evaporated slowly to afford a white powder
of RR505 (5.5 g, 65 % yield). 1H-NMR (400 MHz, D2O):
7.60 (1H, d, J = 8.8 Hz), 7.79 (1H, d, J = 8.8 Hz), 8.08
(1H, s), 8.53 (1H, s), 8.64 (1H, s), 1H-NMR (400 MHz,
DMSO-d6): 7.58-7.66 (2H, m), 7.96 (1H, s), 8.24 (1H, s),
8.26 (1H, s), 10.81 (1H, s). 13C-NMR (100 MHz, D2O):
112.3, 118.8, 121.6, 121.64, 121.7, 124.5, 124.7, 125.5,
133.7, 134.7, 136.9, 142.1.
Synthesis of Carbazole-1,3,6,8-tetrasulfonic acid,
tetrasodium salt (RR506)
Solid carbazole (3.0 g, 17.9 mmol) was placed in a 50-
mL round-bottom flask and chlorosulfonic acid (41.7 g,
358 mmol) was added in small portions with vigorous
shaking at 22 °C, after which the mixture was stirred
and heated at 100 ± 5 °C for 1 h. The resulting dark solu-
tion was cooled to room temperature and then poured
slowly onto crushed ice (~100 g). The resulting precipi-
tate was filtered by gravity filtration and was dried by
placing between paper towels. The resulting semi-dried
solid was dissolved in ethyl acetate (150 mL), treated
with Norit (1.5 g), and refluxed for 15 min and filtered
hot through a pad of silica gel (~1x1.8 inch). The filtrate
was concentrated in vacuo and recrystallized from a 1:9
mixture of ethyl acetate and hexanes to afford a yellow
solid, which was filtered and dried in vacuo.
The dried solid was dissolved in a mixture of dioxane
(20 mL) and distilled/deionized water (20 mL) and heated
under reflux for 12 h. The resulting solution was cooled
to room temperature and was extracted with diethyl
ether (2 x 50 mL) to remove nonpolar impurities. The
aqueous layer was neutralized by a dropwise addition of
NaOH solution (1 M) with continuous monitoring of pH
using pH paper. The resulting solution was concentrated
to ~10 mL and acetone was added to afford a white
powder of RR506 (3.5 g, 22 % yield, average yield from
3 runs). 1H-NMR (400 MHz, D2O): 8.12 (2H, s), 8.68
(2H, s), 1H-NMR (400 MHz, DMSO-d6): 7.97 (2H, s),
8.26 (2H, s), 10.61 (1H, s); 13C-NMR (100 MHz, D2O):
121.9, 122.1, 123.8, 125.7, 134.7, 136.7.
Alternative synthesis of RR506
Solid carbazole (1.0 g, 6 mmol) and nitrobenzene
(20 mL) were placed in a 50-mL round-bottom flask and
chlorosulfonic acid (14 g, 120 mmol) was added in small
portions at 22 °C, after which the mixture was stirred at
22 °C for 72 h. The resulting solution was poured into
aqueous saturated NaCl solution (100 mL) containing
NaOH (0.96 g, 24 mmol) which resulted in a fluffy pre-
cipitate. The precipitate thus formed was filtered and
dried. The solid was dissolved in distilled/deionized
water (100 mL) and refluxed with 1.5 g of Norit for
15 min and filtered hot through a pad of celite. The
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filtrate was concentrated to ~25 mL and RR506 was
precipitated by addition of acetone. The precipitate was
filtered and dried to afford RR506 as a white solid
(2.9 g, 84 % yield). 1H-NMR (400 MHz, D2O): 8.12 (2H,
s), 8.68 (2H, s), 1H-NMR (400 MHz, DMSO-d6): 7.97
(2H, s), 8.26 (2H, s), 10.60 (1H, s).
Protein production
The DUSP5 PD gene was synthesized by Blue Heron
(Bothell, WA) in both an active wild type form (DUSP5
PD(WT)) and an inactive form, where the catalytic cyst-
eine was mutated to a serine (DUSP5 PD(C263S)). The
genes were inserted into Origene pEX plasmids with
ampicillin resistance and an N-terminal hexa-histidine
tag to facilitate protein purification. Plasmids were trans-
formed into BL21(DE3) cells (Invitrogen) for expression.
For unlabeled DUSP5 PD(WT) preparation, an over-
night culture was used to inoculate 2 L of LB (Luria-
Bertani) media, containing 50 μg/mL of ampicillin. Cells
were grown at 37 °C to an OD600 of 0.7 and then induced
with 0.6 mM isopropyl β-D-1-thiogalactopyranoside
(IPTG) for 4 h at 37 °C, then for 14 h at 16 °C. Cells were
harvested using centrifugation and frozen prior to purifi-
cation. Thawed cells were lysed in a buffer containing
50 mM Tris, 300 mM NaCl, 5 mM imidazole, and 10 %
glycerol at pH 7.8. Lysate was centrifuged at 15,000 rpm
for 1 h. The supernatant was loaded on to Ni-Sepharose
Fast Flow resin (GE Healthcare) and washed three times
successively with five column volumes of lysis buffer con-
taining 25 mM imidazole. Protein was eluted with lysis
buffer containing 305 mM imidazole. Protein was then di-
alyzed in a buffer containing 50 mM potassium phosphate
and 2 mM dithiothreitol (DTT) at pH 6.8.
For 15 N-labeled DUSP5 PD(C263S) preparation (for
NMR titrations), an overnight culture was used to in-
oculate 2 L of LB media supplemented with 50 μg/mL
of ampicillin. Cells were grown to an OD600 of 0.7 at
37 °C, then harvested and washed with M9 minimal
media (pH 7.0) [26]. Cells were resuspended in 500 mL M9
minimal media containing 0.5 g 15NH4Cl, 2 g D-glucose,
5 mL Basal Medium Eagle with Earle’s salts and sodium
bicarbonate (Sigma Aldrich), 0.146 g L-glutamine (Sigma
Aldrich) 1.0 mL 1 M MgSO4, and 0.5 mL 1 M CaCl2
(pH 7.2) [30]. Additionally, a metal mix containing Zn,
Mn, Cu, Co, B, and Mo salts was added to supply cells with
necessary micronutrients [30]. Cells were allowed to accli-
mate for 30 min at 37 °C, then induced with 1 mM IPTG
for an additional 4 h at 37 °C. Cells were harvested and 15
N-labeled protein was purified as described before with the
addition of 2 mM DTT during all purifications steps.
p-nitrophenol phosphate (pNPP) activity assay
To measure enzymatic activity of the DUSP5 PD and
the inhibitory capacity of selected molecules, an in vitro
phosphatase assay was developed based on previous stud-
ies [31]. In this assay, DUSP5 PD will dephosphorylate the
substrate p-nitrophenol phosphate (pNPP, Sigma Aldrich),
yielding p-nitrophenolate, which absorbs at 405 nm with
an extinction coefficient of 18,000 M−1 cm−1.
Thus, an increase in absorbance at 405 nm corresponds
to the turnover of pNPP to p-nitrophenolate. The assay
was initially optimized in 1 mL quartz cuvettes, then was
subsequently optimized for and validated in a 96-well
plate format. All IC50 values were obtained using the 96-
well plate assay format (see below). The assay buffer con-
tained 100 mM Tris, 100 mM sodium chloride, 5 mM
magnesium chloride, and 1 mM DTT at pH 7.5. The
pNPP substrate was prepared as a 50 mM stock by dis-
solving the solid substrate in assay buffer. The DUSP5 PD
and pNPP were assayed initially in a cuvette (1 mL total
volume) and initial velocities were fitted to the Michaelis-
Menten equation:
v ¼ Vmax S½ 
Km þ S½  ð1Þ
where v is the initial velocity, Vmax is the maximum vel-
ocity, Km is the Michaelis constant, and [S] is the concen-
tration of pNPP. Data were fitted using a nonlinear least
squares fit to eq. 1, with GraphPad Prism 6 software.
Validation of pNPP assay for high throughput screening
(HTS)
For the 96-well plate validation assay, sodium orthova-
nadate (Sigma Aldrich) was utilized as a positive control
for inhibition [32] at a final concentration of 10 μM, to
completely block DUSP5(WT) enzymatic activity. All
plate assays were performed in standard 96-well clear
bottom plates (Thermo Scientific Nunc) with a total
assay volume of 200 μL, using a SpectraMax M5 Micro-
plate Reader (Molecular Devices). The plate validation
assay was performed with replicate columns of positive
control wells, negative control wells and blank wells.
Blank columns contained only buffer and pNPP. Negative
control (uninhibited) contained buffer, pNPP, and DUSP5
PD(WT); and, positive control contained the same com-
ponents, but also contained 10 μM sodium orthovanadate.
The plate was then shaken and allowed to equilibrate
in the spectrophotometer at 25 °C for 30 min. After
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incubation, 4 μL of a 50 μM enzyme stock was dis-
pensed into appropriate wells utilizing a single-channel
pipette. This produced a final enzyme concentration of
1 μM. Before a read was taken, the plate was shaken
for five seconds. The initial rate for the DUSP5
PD(WT) reaction was linear for approximately 90 min;
and, the plate was kept in the spectrophotometer at
25 °C for an additional 80 min after the kinetic read.
The endpoint reading was subsequently taken at
90 min after initiation of reaction.
Slopes from the kinetic read, as well as single-point
absorbance values at the 90-minute endpoint read, were
then averaged. For blank wells and positive control wells,
both slope values (continuous assay) and single point ab-
sorbance values (fixed time assay) were approximately
zero, as expected (Table 2). Standard deviations were
calculated and a Z’ value [33] subsequently determined
using the following equation:
Z0 ¼ 1− 3 σp þ σn
 
μp−μn


ð2Þ
where σp is the standard deviation for the positive con-
trol, σn is the standard deviation for the negative control,
μp is the mean for the positive control, and μn is the
mean for the negative control. The Z’ value is a coeffi-
cient denoting the quality of a high throughput screen-
ing assay, reflecting both the variation in data and
dynamic range for the assay. A good assay exhibits a
high signal to background ratio. A Z’-factor of 1.0 re-
flects an ideal assay; and, for an assay to be considered
reliable, must exceed 0.5 [33].
IC50 measurements
IC50 values were obtained using the assay described
above, in 96 well plates. The maximum inhibitor con-
centration screened in any plate was 300 mM and the
minimum screened concentration was 1 μM. The IC50
plate was designed so that the first column of wells
served as blanks, with wells containing only buffer and
substrate. The second column of wells functioned as the
plate negative control, with each well containing buffer,
substrate and enzyme. The remaining wells in the plate
contained buffer, substrate, enzyme, and varying amounts
of inhibitor, with inhibitor concentration increasing from
left to right across the plate. Data points were collected at
a minimum in triplicate, and inhibitor concentrations
were chosen to provide data equally spread on a logarith-
mic scale. The composition of buffer and the concentra-
tions of substrate and enzyme utilized were identical to
those in the plate validation assay. After initiation and
shaking, a ten-minute kinetic read was taken.
For each plate assayed, the slope values for all negative
control wells were averaged and the measured value
considered representative of full enzymatic activity. Frac-
tional activity was then calculated by dividing the slope
of each inhibitor well by this value, determining the rela-
tive amount of enzyme activity observed at each concen-
tration of inhibitor. Values were then plotted as percent
activity versus the log of the concentration of inhibitor,
and fitted to the following equation:
y ¼ Bottom þ Top−Bottomð Þ
1þ 10x− logIC50 ð3Þ
where Top and Bottom are plateaus for the values of initial
velocity when uninhibited and fully inhibited, respectively.
Nephelometry
Nephelometry is a technique for measuring the relative
aggregation of particles in solution, based on the light-
scattering properties of molecular aggregates [34]. We
performed nephelometry to explore the ability of the
chemicals studied herein to form aggregates, which can
lead to artifactual inhibition effects. Compounds were
tested for aggregation in 96-well plates using a buffer
containing 100 mM Tris base, 100 mM sodium chloride,
and 5 mM magnesium chloride at pH 7.5. Each com-
pound analyzed in these experiments contained concen-
trations of compound ranging from 10-100 μM, recorded
in quadruplet. Each plate was analyzed at two separate
gain values of 52 and 72. Data were collected using a
BMG NEPHELOstar Plus, equipped with a 635 nm laser.
NMR binding assay
NMR samples of DUSP5 PD(C263S) were prepared for
2D 1H-15N HSQC (heteronuclear single quantum coher-
ence) spectral titration studies. The 15 N-labeled DUSP5
PD(C263S) protein was concentrated using an Amicon
Ultra-4 centrifugal device (Millipore) to 600 μM. NMR
samples were prepared with the following conditions for
RR505: 250 μM RR505, 250 μM DUSP5 PD(C263S),
10 % D2O, 50 mM potassium phosphate, 100 mM KCl,
and 2 mM DTT at pH 6.8 and for CSD3-2320: 0 or
500 μM CSD3-2320, 500 μM DUSP5 PD(C263S), 10 %
D2O, 50 mM potassium phosphate, 100 mM KCl, and
2 mM DTT at pH 6.8. NMR experiments were per-
formed on a 500 MHz Varian NMR System using a
triple resonance probe with z-axis gradients at 25 °C.
ERK dephosphorylation assay
For this assay, 10 ng of GST-tagged recombinant phos-
phorylated ERK2 (R&D Systems, 1230-KS) was incubated
with and without the indicated DUSP5 proteins (0.5 nM
final concentration) for 15 min at room temperature, with
or without the indicated drugs. The reactions were halted
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with 2x Laemmli sample buffer and subjected to SDS-
PAGE. The proteins were transferred to polyvinylidene
difluoride (PVDF) and immunoblotted using antibodies to
pERK (Cell Signaling Tech., #9106) and total ERK, which
includes both phosphorylated and unphosphorylated
ERK1 and ERK2 (Cell Signaling Tech., #9102). Bound
antibodies were visualized using horseradish peroxidase-
linked anti-mouse IgG (Cell Signaling Tech, #7076S) and
anti-rabbit IgG (Cell Signaling Tech, #7074S), respectively,
and ECL reagents (Pierce, #34708) according to the manu-
facturer’s protocol. For calculating IC50 values, gel bands
were imaged by chemiluminescence with either film or
digital image capture by a FluorChem HD2 imager (Alpha
Innotech). Density of each band was quantified with
ImageJ software by using the gel analysis tool. Relative
values of phosphorylated ERK present for each drug
concentration treatment compared to pERK only con-
trols were calculated. These relative values were then
used to obtain IC50 values with GraphPad Prism 6 soft-
ware. Each experiment was repeated at least three inde-
pendent times, and IC50 values provided as a range.
Results
Docking and ligand-based in silico searches yield candidate
small molecules that target the DUSP5 PD domain
In this study, we were interested in identifying inhibitors
that could selectively target dual-specificity phosphatase
5 (DUSP5), which we have shown previously to be mu-
tated in patients with vascular anomalies. As shown in
Fig. 1a, DUSP5 contains two domains namely an ERK-
binding domain (EBD) and a phosphatase domain (PD)
that are fused together by an unstructured linker region.
The X-ray structure of PD of human DUSP5 was previ-
ously reported (PDB:2G6Z) [16], while the structure of
EBD was constructed using homology modeling based
on the solution structure (21 % identity and 35 % hom-
ology) of human MKP-3 protein (PDB:1HZM) as a tem-
plate [35]. The 30 amino acid linker region connecting
the two domains, which is of unknown structure, was
prepared manually. A model of the human DUSP5-
ERK2 complex (Fig. 1b) illustrates how DUSP5 (blue)
wraps around ERK2 (yellow), its natural substrate, with
the EB and PD DUSP5 domains located on opposite
sides of ERK2. The model was prepared as described in
our previous paper [8], and the relative orientation of
ERK2 and DUSP5 is based on molecular dynamics simu-
lations described previously [8].
In order to identify inhibitors for DUSP5, we per-
formed in-silico docking of 11,500 chemicals from the
CSD3 in-house collection into the PD domain of DUSP5.
The docking procedure produced a rank-ordered list of
compounds that were tested using the pNPP assay (dis-
cussed below). One promising compound, SM1842—a
trisulfonated carbazole, displayed attributes associated
with lead-like chemicals (e.g. molecular weight; LogP)
[36]. The 1H NMR spectrum of the commercially
sourced SM1842 sample did not match the expected
signal pattern for trisulfonated carbazole (Additional file 1:
Figure S1), and therefore this compound was resynthe-
sized and its spectrum was compared with the spectrum
of commercial SM1842. The resynthesized compound,
RR505 (Table 1), displayed the expected 1H NMR
spectrum for the trisulfonated carbazole. An additional
synthesis of a tetrasulfonated carbazole RR506 (i.e. an
extra sulfonate, relative to SM1842, Table 1) and compari-
son of its 1H NMR spectrum with that of the commercial
SM1842 demonstrated that the commercial sample was
(largely) a mixture of RR505 and RR506, i.e. the tri- and
tetrasulfonated carbazoles (see Table 1). Further experi-
mental analysis made use of only pure samples, i.e. RR505
and RR506.
The docking pose from the lowest energy cluster
for RR505 (SM1842) had a calculated binding energy
of −9.69 kcal/mol and a cluster size of 10 (Fig. 2a).
Using the chemical structure of RR505 as a search tem-
plate, additional chemical libraries were computationally
screened to identify related structures that could also be
tested. One such compound, naphthalene trisulfonate
(Table 1, NTS), was identified from the in-house collec-
tion of chemicals as well as from the ZINC collection [27]
of commercially available chemicals. This compound was
identified using ROCS [26], which matches chemical quer-
ies to compounds in chemical libraries based on molecu-
lar shape and electrostatic properties. Figure 2b shows the
overlay of RR505 and NTS, using ROCS. NTS docked
similarly to RR505 in the DUSP5 PD active site pocket
(Additional file 1: Figure S2A). Interestingly, the lowest
energy poses for NTS (−8.48 kcal/mol, cluster population
of 7, Additional file 1: Figure S2B) and RR505 show a
flipped binding mode relative to each other (Fig. 2c and
d). We hypothesize based on the ROCS alignment (Fig. 2b)
that the docking algorithm would position the ligands
similarly. While this is not the case for the lowest energy
cluster, it is the case for the second lowest energy cluster.
Similarly, RR506 was flipped relative to the lowest energy
cluster pose of RR505 (Additional file 1: Figure S2C). And
again, the second lowest energy cluster pose for RR506
(Additional file 1: Figure S2D) matched that of the lowest
energy pose of RR505.
Expression, purification and assay of the DUSP5 PD
domain
To assess the activity of the identified compounds from
in-silico docking, we expressed and purified the phos-
phatase domain of DUSP5 protein referred to as DUSP5
PD(WT) (Additional file 1: Figure S3), and tested it in
an enzymatic assay with p-nitrophenyl phosphate
(pNPP) as a substrate. Protein was expressed in E. coli
Neumann et al. BMC Biochemistry  (2015) 16:19 Page 7 of 16
and purified as described above. SDS-PAGE gel analysis
of DUSP5 PD(C263S) indicates >95 % purity (Additional
file 1: Figure S3A). The 2D 1H-15N HSQC NMR spectrum
for a sample of the DUSP5 PD(C263S) protein shows
good chemical shift dispersion, indicating the protein
is well-folded (Additional file 1: Figure S3B). We also
Table 1 Structures, Docking Energies, and IC50 Values of DUSP5 PD Inhibitors
Chemical structure Docking energy (kcal/mol) IC50 from enzyme assay
SM1842 −9.69 5.1 ± 1.9 mM
−9.69 26 ± 3 mM
RR505
−9.89 16 ± 2 mM
RR506
−8.48 6.4 ± 0.8 mMa
Naphthalene trisulfonate (NTS)
NA 44 ± 6 μMa (Ki = 25 ± 5 μM)
a
Suramin
aObtained in absence of Triton X-100
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obtained 2D 1H-15N HSQC NMR spectra in the presence
of 250 μM RR505 (Additional file 1: Figure S3C) and
observed cross-peak shifting or exchange broadening,
consistent with direct binding of RR505 to 15 N-labeled
DUSP5 PD(C263S). To assess the ability of the com-
pounds identified via docking to inhibit DUSP5 PD
(WT) activity, a phosphatase assay was developed based
on a previously published assay [31, 37]. The substrate,
pNPP, has been shown to react with a wide variety of
phosphatases [38]. The assay was performed in 1-mL
quartz cuvettes, at various substrate concentrations, and
initial velocities were measured at the wavelength of
405 nm due to the formation of p-nitrophenolate. Initial
velocity data were fitted to the Michaelis-Menten equation
(Fig. 3a), yielding a Vmax of 1.35 ± 0.02 × 10
−3 (μmol/min)
and a Km of 7.6 ± 0.4 mM. Since some of the inhibitors to
be screened were dissolved in DMSO, the effect of 1, 2,
and 4 % DMSO was investigated by substituting appropri-
ate quantities of DMSO for some of the buffer mixture.
Relative rates with and without DMSO were compared
and plotted in Fig. 3b. DMSO appears to activate the
DUSP5 PD reaction, consistent with a previous report for
DUSP6 [39]. Thus, to ensure consistent results we per-
formed all assays on compounds dissolved in DMSO while
maintaining a fixed concentration of DMSO.
To measure IC50 values, a control inhibitor was used,
and the assay was performed with the addition of a known
broad-spectrum inhibitor of phosphatases, sodium ortho-
vanadate (vanadate) [29]. Initial experiments were per-
formed in 1 mL cuvettes and concentrations of vanadate
were varied. Initial velocities from kinetic reads were
plotted as a function of the log of vanadate concentration
and fitted to equation 3, to obtain the IC50 of 88 ± 8 nM
(Additional file 1: Figure S4).
Development of HTS assay for screening inhibitors and
validation
The pNPP phosphatase assay was also performed in a
plate format to increase throughput by which inhibitors
could be screened. To validate the plate assay, the Z’ factor
[33] was determined using the plate arrangement de-
scribed above. The absorbance values for the end-point
assays and the slopes for the kinetic assays were averaged
(summarized in Table 2), and Z’ values were calculated
using equation 2. Both the end point assay (Z’ = 0.73) and
the kinetic assay (Z’ = 0.74) formats resulted in Z’ factors
in the acceptable range for an HTS assay.
Compounds identified by protein-based (docking) and
ligand-based (ROCS overlays) in silico screening methods
were tested experimentally using the plate assay described
Fig. 2 Docking Results. a Predicted docking pose of SM1842/RR505 (gold) in DUSP5 PD (blue), using Autodock 4.2. The inset image shows
predicted binding position relative to the rest of the protein. The side chains around the bound ligand (mostly arginine guanido groups) are
delineated in light turquoise and the catalytic cysteine is displayed in yellow. Three arginine residues are observed around one sulfonate group of
SM1842/RR505. The calculated binding energy for this pose was -9.69 kcal/mol and had a cluster population of 10. b Optimal overlay of
SM1842/RR505 (gold) and naphthalene trisulfonate (NTS, moss green), using OpenEye Scientific Software ROCS v. 3.0 [26]. c Lowest energy
binding pose for NTS (moss green) in DUSP5 PD (blue), with a calculated binding energy of -8.48 kcal/mol with a cluster population of 7. d
Second lowest energy binding pose for NTS (seafoam), with a calculated binding energy of -8.21 kcal/mol. e Ligplot drawing of SM1842/RR505
in the DUSP5 PD binding pocket, showing key interactions
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above. Initial velocities were measured for the first 10 min
of reaction, plotted (Fig. 4), and then fitted to equation 3
to obtain IC50 values (summarized in Table 1). We tested
SM1842 (RR505 +RR506), RR505 and RR506 in the
HTS pNPP assay. Triton X-100 was used in this assay (at
0.1 %) to disrupt any small molecule aggregates that could
be formed. The IC50 for SM1842 is 5.1 mM, while for
RR505 and RR506 is 26 and 16 mM respectively (Fig. 4a;
Table 1). Collectively, these data suggest that SM1842 or
its analog mixture identified from the computational
docking assay inhibit DUSP5 in the mM IC50 range.
Suramin, an FDA approved analog, was identified via lead
hopping
To identify molecules with similar shape and electro-
static properties to NTS (IC50: 6.4 mM in pNPP assay)
(Fig. 4b), we subsequently searched a Drugbank [28, 29]
(chemical library that contains structures of FDA ap-
proved drugs) using ROCS with the RR505 and NTS
structures. Suramin was found as a match to the NTS
structure. Indeed, suramin (Table 1) is comprised of two
NTS substructures connected via a rigid linker, and is an
FDA approved drug that is used to treat African sleeping
sickness [40]. Initial velocity inhibition profiles of sura-
min were obtained by measuring initial velocities at var-
ied concentrations of substrate (pNPP) and inhibitor
(suramin) (Additional file 1: Figure S5). The inhibition
profile fits best to the equation for competitive inhib-
ition (eq. 4).
v ¼ Vmax S½ 
Km 1þ I½ Ki
 
þ S½ 
ð4Þ
where v is the initial velocity, Vmax is the maximum vel-
ocity, Km is the Michaelis constant, and [S] is the con-
centration of pNPP. The data were fitted to the equation
for competitive inhibition, to give a Ki of 24.6 ± 5.2 μM
(Additional file 1: Figure S5). Competitive inhibition sug-
gests that inhibition occurs via specific blockage of the
Fig. 4 IC50 Measurements. a DUSP5 PD(WT) initial velocity versus
inhibitor concentration, and fitted to equation 3 to obtain IC50
values (Table 1). Conditions were as described for Fig. 3. (b) Same as
panel (a), but comparing suramin and NTS, demonstrating the
affinity increase that is obtained due to tethering the NTS fragments
Table 2 DUSP5 PD(WT) pNPP enzymatic assay data for Z’
calculation (96 well plates)
a) End-point assay after 90 min
Positive control Negative control
Mean 0.006 0.269
Standard deviation 0.004 0.02
b) Kinetic (continuous) assay over 5 min
Positive control Negative control
Mean −0.035 3.28
Standard deviation 0.091 0.193
Fig. 3 Michaelis-Menten Kinetics. a Michaelis-Menten plot of DUSP5
PD(WT) initial velocity versus substrate (pNPP) concentration, monitoring
production of p-nitrophenolate at 405 nm. Reaction was in 100 mM
Tris-HCl (pH 7.5), 100 mM NaCl, 5 mM MgCl2 and 1 mM DTT, and was
initiated with enzyme. The line represents a nonlinear least squares fit
to equation 1. b Enzymatic rate as a function of DMSO concentration
(% v/v), and at a fixed level of pNPP (5 mM), with other conditions as in
panel (a). Relative enzyme activation represents the rate normalized to
that obtained at 0 % DMSO
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phosphatase active site (suramin competes for pNPP
binding in the phosphatase active site). Aggregation is
often an issue with small molecules, so we investigated
whether suramin aggregates in solution. To test for ag-
gregation, the assay was repeated in the presence of Tri-
ton X-100, a detergent that is able to break up small
molecule aggregates, while not significantly interfering
with the assay [41]. NTS (Fig. 5a) and suramin (Fig. 5b)
inhibition was compared under identical conditions in
the absence and presence of Triton X-100. Results show
that detergent decreases suramin inhibition, while it has
no effect on NTS inhibition. This indicates that at least
some of suramin’s inhibition is due to aggregation, and
that this tendency to aggregate is not an inherent prop-
erty of just the polysulfonated aromatic group contained
within the suramin molecule (NTS). But, while the level
of inhibition due to suramin decreases in the presence
of added detergent, it is not eliminated (Fig. 5c). This
suggests that while suramin aggregates, at least some of
its inhibition is not due to aggregation, consistent with
the fact that suramin behaves as a competitive inhibitor
(nonspecific inhibition would not appear competitive).
We additionally confirmed the potential aggregating
effects of suramin and other compounds using nephe-
lometry methods. When an inflection occurs in the Rela-
tive Nephelometry Units, measured as a function of
compound concentration, this indicates that the particle
size in solution is increasing, due to aggregating effects.
RR505, RR506, NTS, and suramin were subjected to
nephelometry measurements (Additional file 1: Figure S6).
Suramin appears to start forming aggregates around
25 μM, while RR505, RR506 and NTS do not appear
to form aggregates. This is consistent with the Triton
X-100 studies that suggest that suramin inhibition, un-
like NTS, is at least partially due to aggregation effects.
Identification of small molecule inhibitors based on
distance between sulfates in the DUSP5 PD active site
All compounds identified thus far have had two or more
sulfonate groups on a polycyclic aromatic core structure.
Recognition of this common theme amongst ligands,
and inspection of the active site pocket of the crystal
structure of the human DUSP5 PD [16], led us to a hy-
pothesis regarding the required pharmacophore features
of DUSP5 PD ligands. Since the DUSP5 PD crystal
structure contains two sulfate ions in the active site
pocket (Fig. 6a) in the regions suggested to be occupied
by the di-phosphorylated substrate (pThr-Glu-pTyr, of
ERK2), and our ligands generally possessed at least two
sulfonates (Table 1), we reasoned that two such nega-
tively charged moieties—appropriately positioned—are a
necessary feature of any DUSP5 PD inhibitor. To this
end, a ligand-based search strategy based on the two
bound sulfate ions was then pursued. These sulfate ions
are positioned 7.2 Å from each other (Fig. 6a), with one
located where the phosphate to be cleaved would reside
Fig. 5 Effect of Detergent on Suramin Inhibition. a NTS IC50 measurement in the presence and absence of 0.5 % Triton, showing no detergent-effect on
inhibition of DUSP5 PD(WT) pNPP phosphatase activity. b Suramin IC50 measurement in the presence and absence of 0.5 % Triton X-100 shows
a loss of some inhibitory capability in the presence of detergent. c Effect of increasing detergent levels (Triton X-100) on rate of DUSP5 PD(WT)
in the presence of a fixed concentrations of inhibitor and substrate (at 1 μM suramin and 5 mM pNPP). Detergent removes some, but not all, of
suramin’s inhibitory effect, showing a plateau level 30 % inhibition
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(this site is called S1), proximal to the Cys263 nucleo-
phile (Fig. 6a). The other, termed S2, is located 7.2 Å
away, in an arginine-rich pocket. Overlay of compound
RR505 with the S1 and S2 sulfates was less than optimal
(Fig. 7b), while the NTS overlay was better (Fig. 6c). A
ROCS search was made of all compounds in the CSD3
internal collection for hits that had sulfonates in the
proper S1;S2 location, and compound CSD3_2320 was
identified (Fig. 6d). This compound (like NTS) is based
on the simpler naphthalene core, and has an IC50 of
32.7 ± 2.3 mM (Fig. 7a) in the phosphatase assay with
DUSP5 PD(WT) and using pNPP as substrate. But, in
the more biologically relevant assay with full length
DUSP5 and using pERK2 as substrate, the IC50 is in the
range of 8–96 μM with a mean of 33 ± 21 μM (Fig. 7b).
The 1D 1H NMR spectrum confirms that CSD3_2320 is
pure (Additional file 1: Figure S7) and matches the ex-
pected structure; and, nephelometry indicates that it has
no propensity to aggregate (Additional file 1: Figure S8).
NMR HSQC titration experiments (Fig. 7c) confirm direct
binding to DUSP5 PD(C263S), with several crosspeaks
being shifted in the presence of CSD3_2320. When
CSD3_2320 is positioned in the model of the ERK2-
DUSP5 complex (Fig. 1) by overlaying the sulfonates on
the phosphate groups of the ERK2 activation loop, a close
superposition is obtained that positions the phenolic ring
of the CSD3_2320 naphthalene core where the tyrosine
would bind (Fig. 7d), with the hydroxyl group in the vicin-
ity of where the incoming water nucleophile would be lo-
cated, before attack on the substrate’s phosphate ester.
CSD3_2320 was also screened against a panel of 21 phos-
phatases and found to not inhibit any of them significantly
at up to 30 μM (Additional file 1: Figure S9).
Discussion
Docking and HTS assay to identify polysulfated lead
molecules
Docking into the phosphatase domain (PD) of the full-
length DUSP protein (Fig. 1) and ROCS alignment cal-
culations have identified various polysulfonated aromatic
compounds, with both carbazole and naphthalene scaf-
folds (Fig. 2; Table 1; Fig. 6e). In order to determine
Fig. 6 Pharmacophore-based Identification of DUSP5 PD Inhibitors. a Crystal structure of DUSP5 PD(C263S) [16], showing the two bound sulfate
ions in the two anion-binding pockets postulated to be occupied by the two phosphate groups of the ERK2 activation loop (pThr-Glu-pTyr)
[16–18]. The anion pocket closest to the catalytic nucleophile (Cys263) is labeled S1, and the distal anion pocket is labeled S2. The S2 anion (sulfate) is
stabilized be several arginine residues, while the S1 anion may derive some helix dipole stabilization by virtue of its location at the N-terminal end of a
long central helix. The sulfur to sulfur distance of 7.2 Å defines the DUSP PD pharmacophore as two anionic groups separated by ~7 Å. Overlay of the
S1-S2 pharmacophore (two sulfates, shown as purple) on RR505 indicates a poor match, while (b) overlay on NTS (c) in one of two possible orientations
(related by a 180° rotation) is better. d A ligand-based search using this pharmacophore identified CSD3_2320, which also matched the S1-S2 sulfate
positions well. The overlay in panel (d), as in panel (c), is shown in one of the two possible orientations that optimally align active site sulfate and
ligand sulfonate groups. e Flow chart summarizing the docking and ROCS alignment procedures used to identify lead molecules. Once SM1842/RR505
was identified from the CSD3 Library, it was used as a ROCS query and searched against the CSD3 Library and ZINC Library. NTS was identified from the
ROCS search. NTS was used as a ROCS query to search Drugbank, which led to identification of Suramin
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affinity of compounds identified using docking studies,
an enzyme inhibition (IC50) assay was developed whereby
dephosphorylation of pNPP is monitored. pNPP was
found to be a substrate for DUSP PD(WT) with a Km of
7.6 mM (Fig. 3), apparently serving as a mimic of the
natural substrate, the phospho-tyrosine of ERK2. The
DUSP5 PD(WT) IC50 assay using pNPP as substrate
(Fig. 4) was adapted, optimized and validated as a high
throughput screening (HTS) assay, and was found to be
suitable for HTS with a Z’ value > 0.7 (Table 2). Enzym-
atic screening of compounds identified by docking identi-
fied a number of weak-binding polysulfonated inhibitors
that could be used as drug lead scaffolds (Table 1; Fig. 6),
off of which more potent lead molecules could be devel-
oped by rational drug design or by fragment-based drug
design techniques, if proximal binding pockets can be
identified.
Lead-hopping to an FDA approved drug and beyond
We have also employed a novel approach, to transition
from initial lead molecules (SM1842/RR505 and
RR506; Figs. 2 and 4) to an advanced clinical candidate,
by screening for FDA approved compounds that match
the shape and electronic properties of a lead molecule,
using ROCS. Based on this ROCS overlay, naphthalene
trisulfonate (NTS) was found to match the shape and
electronic properties of RR505 (Fig. 2b); and, NTS was
found to be present in the suramin (Table 1), an FDA
approved drug available from Centers for Disease Con-
trol for treating African sleeping sickness [40]. Suramin
is a competitive inhibitor versus pNPP, binding with a Ki
of 25 μM (Additional file 1: Figure S5).
While initially promising, suramin does not exhibit
properties of a good drug lead molecule, even though it
is FDA approved. In particular, while suramin is a rea-
sonably potent competitive inhibitor, it also causes
non-specific aggregation. Based on DUSP5 PD(WT)
IC50 assays performed with and without detergent
(Fig. 5), along with nephelometry studies (Additional
file 1: Figure S6), we conclude that while suramin does
inhibit by direct binding to the phosphatase domain
(Figs. 5b and c), it also forms aggregates in vitro which
can lead to additional non-specific protein inhibition
effects. This aggregation phenomenon raises more glo-
bal concerns regarding the current clinical use of sura-
min, and may in part explain some of the known
toxicity associated with suramin [40]. Indeed, literature
on suramin [35, 41–44] indicates that it can bind to
many protein targets, so may lack specificity in its
mechanism of inhibition.
A C
DB
Fig. 7 CSD3_2320 binding to DUSP5 PD. a Dose response curve for CSD3_2320 as an inhibitor of the DUSP5 PD(WT) phosphatase activity, using
pNPP as substrate. Experimental conditions as in Figs. 3 and 4. Chemical structure of CSD3_2320 in the insert. b Dose response curve for
CSD3_2320 as an inhibitor of the DUSP5 (full-length protein) phosphatase activity, using pERK2 as a substrate. c DUSP5 PD(C263S) 1H-15N HSQC
spectrum of DUSP5 PD( C263S) in pH 6.8, 50 mM potassium phosphate, 100 mM potassium chloride buffer. Overlay is of 500 μM 15 N-labeled
DUSP5 PD alone (black), and in the presence of 500 μM CSD3_2320 (red). Potentially important chemical shift perturbations due to binding are
indicated using arrows. d The model from Fig. 1, with CSD3_2320 positioned such that its two sulfonate groups are optimally overlaid with the
two phosphate groups on the ERK2 pThr-Glu-pTyr peptide. This overlay results in the phenolic ring of the CSD3_2320 naphthalene core being
superimposed directly on the tyrosine phenol ring of the pThr-Glu-pTyr peptide
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DUSP5 inhibition vs. activation: implications for vascular
anomalies
We identified the S147P mutation in DUSP5 in patients
with vascular anomalies [2], which results in a mutant
hypoactive protein [8]. This mutation thus presumably
results in increased pERK levels in the “putative causa-
tive cell,” whose identity is unknown for now. It is pre-
sumptive to imply that this mutation is causative
because: (a) most diseases are not the result of a single
aberration in a gene product, (b) single gene knockouts
in mice and its subsequent phenotype does not necessar-
ily imply causative role in disease, but perhaps the po-
tential functions of the gene product in different tissues,
and (c) finally, the etiology of disease, and the context of
the mutation in the disease needs to reconciled, which is
often not considered. For example, in vascular anomalies
such as hemangiomas, which are thought to be inborn
errors during embryonic development, there are two
phases: the first phase is the increased proliferative
phase or the rapid growth phase, and the second phase
is the involution or the regression phase. The cellular
dynamics, behavior and local milieu in the two phases
are likely to be distinct. Whether DUSP5 functions in
the early or later phase is not known. Because the prolif-
erative phase is the initial phase, and p-ERK is involved
in cell proliferation [5], therefore the natural presump-
tion is that DUSP5 is involved in the first phase. There-
fore, our attempts to inhibit DUSP5 could stop the
disease in the first phase. However, if inhibiting DUSP5
accelerates the disease in the first phase as the putative
tumor suppressor role of DUSP5 would suggest, then,
perhaps the involution second phase of hemangiomas
could be triggered earlier assuming that the two phases
are linked by a common mechanism involving DUSP5.
Therefore, the benefit of inhibiting a “putative tumor
suppressor,” such as DUSP5, and in turn accelerating the
disease etiology to a phase where the disease regresses is
counterintuitive. It is noteworthy that loss of DUSP5
does increase apoptosis of endothelial cells [2, 45],
suggesting that DUSP5 as a survival factor for ECs. This
perhaps occurs in the regression phase of the hemangioma
disease. The debate as to whether to develop activators
or inhibitors of DUSP5 is therefore context dependent,
and probably both have benefits in specific stages of dis-
ease. Irrespective of the strategy, phosphatases as targets
for drug discovery present their unique challenges as
highlighted in the findings in this manuscript. Although
we rationalized on developing DUSP5 inhibitors for vas-
cular anomalies, it is becoming increasingly clear that
DUSP5 inhibitors could be viable for other conditions
especially those associated with immune system. Recent
publications [6, 7] have demonstrated a role for DUSP5
in the immune system. Our unpublished work (Kutty, R,
Ramchandran, R. et al.) also supports these findings.
These studies together underscore the importance of
DUSP5 in a wide array of phenotypes in different tissue
types, with likely more to be discovered in the future.
Charge separation vs. distance hypothesis
While protein-based methods (i.e. docking) have identi-
fied a series of weak binding polysulfonated lead mole-
cules (Table 1) for DUSP5, and lead-hopping with ROCS
has identified the FDA-approved drug suramin, none of
these are viable drug leads without further modification.
Thus, more lead molecules and analogs are needed. An
interesting feature of all these weak-binding lead mole-
cules is the presence of at least two charged sulfonates,
separated by 6–9 Å (Table 1). This led us to hypothesize
that this trend is occurring because the active site pocket
of DUSP5 PD binds a peptide loop from ERK2 contain-
ing two phosphates, so is designed to accommodate two
negatively charged functionalities separated by this ap-
proximate distance. Indeed, DUSP5 PD was found to
crystallize with two sulfate anions bound, at an S-S dis-
tance of 7.2 Å (Fig. 6). These observations led us to con-
clude that the key pharmacophore feature for DUSP5
PD binding is two negatively charged groups (such as
sulfates or sufonates, tethered by a core scaffold (carba-
zole and naphthalenes have been identified herein).
Negatively charged functional groups are commonly ob-
served on phosphatase inhibitors, but are also associated
with poor ability to penetrate cell membranes. Indeed,
the polysulfonate compounds identified herein did not
show activity in our preliminary assays using human
umbilical vein endothelial (HUVEC) cells, which we
speculate is due to their inability to penetrate cell mem-
branes. Thus, future studies will be directed to substitut-
ing the sulfonates with functional groups that are more
likely to penetrate into cells, such as carboxylates, tetra-
zoles or sulfonamides. Using this pharmacophore fea-
ture of two negatively charged groups separated by
7.2 Å in a ligand-based screen, a naphthalene-based dis-
ulfonate compound, CSD3_2320, was identified (Fig. 7).
CSD3_2320 has an IC50 of only 33 mM if assayed using
the phosphatase domain alone (Fig. 7a), but 33 μM if
assayed using the full-length DUSP5 with ERK2 as sub-
strate (Fig. 7b). CSD3_2320 is unique, in that it is the
only compound tested that showed such a dramatic dif-
ference in IC50 values when measured in the two assays,
indicating that it is especially sensitive to conform-
ational differences that may exist in the binding site
pocket in the full length versus the isolated phosphatase
domain. Supporting this argument is the fact that the
full length DUSP5 protein also contains an ERK binding
domain, tethered via a flexible linker (Fig. 1). Also, the
native substrate for DUSP5, namely the ERK2 protein, is
much larger and capable of a wider range of inter-
molecular interactions than the pNPP substrate, which
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is intended only to mimic the phosphotyrosine of pERK.
Thus, while the DUSP5 PD(WT)/pNPP assay is a useful
preliminary screen, a subsequent assay using full-length
DUSP5 and ERK2 substrate provides the in vitro
“physiologically relevant” assessment of potency for a
lead molecule. Importantly, CSD3_2320 shows no ten-
dency to aggregate. Thus, the 7.0–7.5 Å—separated disul-
fonate is a consistent pharmacophore feature for inhibition
of the DUSP5 PD (Table 1), which shows some depend-
ence on the presence of intact DUSP5 protein versus use
of just the phosphatase domain. These and other features
are part of ongoing studies to further improve the potency
of CSD3_2320.
Conclusion
This study illustrates the challenges associated with
structure-based drug design applied to dual-specificity
phosphatases, which have a preference for highly
charged ligands. Screening results presented herein typ-
ically yielded polysulfonated aromatic compounds with
charged groups separated by ~7.2 Å, and included the
FDA-approved drug suramin (Fig. 1). While polysulfo-
nated aromatic compounds often aggregate like suramin,
careful secondary screens using nephelometry and deter-
gent have allowed for the identification of authentic
competitive inhibitors, such as CSD3_2320. The potency
of CSD3_2320 under the more biologically relevant con-
ditions of the DUSP5 (full-length)/pERK2 assay is
33 μM. CSD3_2320’s sulfonate groups are positioned
7 Å apart, to mimic the two phosphates on the ERK2 tri-
peptide substrate (pThr-Glu-pTyr). CSD3_2320 is a suit-
able scaffold upon which to build more potent and
selective DUSP5 inhibitors; but, in any such inhibitor
optimization effort, it will be crucial to perform secondary
assays using the full-length DUSP5 protein, and using
nephelometry and detergent screens to eliminate com-
pounds that show the nonspecific aggregation effects
common to sulfonates.
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